stoxline Quote Chart Rank Option Currency Glossary
Gritstone bio, Inc. (GRTS)
0.7366  -0.007 (-0.95%)    04-19 16:00
Open: 0.746
High: 0.775
Volume: 1,518,568
Pre. Close: 0.7437
Low: 0.7088
Market Cap: 78(M)
Technical analysis
2024-04-19 5:09:51 PM
Short term     
Mid term     
Targets 6-month :  2.42 1-year :  3.43
Resists First :  2.07 Second :  2.94
Pivot price 1.01
Supports First :  0.67 Second :  0.55
MAs MA(5) :  0.74 MA(20) :  1.42
MA(100) :  2.04 MA(250) :  1.99
MACD MACD :  -0.5 Signal :  -0.4
%K %D K(14,3) :  3.2 D(3) :  3.2
RSI RSI(14): 24.8
52-week High :  3.32 Low :  0.67
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GRTS ] has closed above bottom band by 32.2%. Bollinger Bands are 43.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.78 - 0.78 0.78 - 0.79
Low: 0.7 - 0.7 0.7 - 0.71
Close: 0.73 - 0.74 0.74 - 0.75
Company Description

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Headline News

Sat, 20 Apr 2024
Gritstone bio (NASDAQ:GRTS) shareholders have endured a 70% loss from investing in the stock three years ago - Yahoo Lifestyle UK

Thu, 18 Apr 2024
Gritstone bio, Inc. (GRTS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek ... - AccessWire

Thu, 18 Apr 2024
Equities Analysts Issue Forecasts for Gritstone bio, Inc.'s Q1 2024 Earnings (NASDAQ:GRTS) - Defense World

Thu, 18 Apr 2024
Research Analysts Offer Predictions for Gritstone bio, Inc.'s Q2 2024 Earnings (NASDAQ:GRTS) - Defense World

Wed, 17 Apr 2024
Investors in Gritstone bio (NASDAQ:GRTS) have unfortunately lost 66% over the last three years - Yahoo Movies Canada

Mon, 08 Apr 2024
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 106 (M)
Shares Float 91 (M)
Held by Insiders 2.2 (%)
Held by Institutions 40.2 (%)
Shares Short 9,120 (K)
Shares Short P.Month 8,220 (K)
Stock Financials
EPS -1.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.52
Profit Margin 0 %
Operating Margin -293.5 %
Return on Assets (ttm) -41.8 %
Return on Equity (ttm) -124.5 %
Qtrly Rev. Growth 143.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.15
EBITDA (p.s.) -1.25
Qtrly Earnings Growth 0 %
Operating Cash Flow -122 (M)
Levered Free Cash Flow -80 (M)
Stock Valuations
PE Ratio -0.62
PEG Ratio 0
Price to Book value 1.38
Price to Sales 4.79
Price to Cash Flow -0.65
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android